AB Sciex Buys Labindia's Mass Spec Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AB Sciex has acquired Labindia's mass spectrometry business for an undisclosed sum in a deal that the two firms said represents AB Sciex's deepening investment into India's scientific community.

AB Sciex said today that the purchase of the Delhi-based services provider is the result of a successful ongoing partnership between the companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.